English Medical Medical: Pharmaceuticals

Context: Composite Clinical Benefit End Points. A composite end point may be appropriate when the drug¡¯s benefit is multifaceted. The end-point components should be related and generally of similar clinical importance. Pamidronate was the first bisphosphonate drug approved to decrease morbidity of skeletal metastases£» it was initially approved for myeloma and, subsequently, for breast cancer. The applicant developed the end-point SREs, which included one or more of the following£º pathologic fractures, radiation therapy for local pain, surgery to stabilize near-fractures, or spinal cord compression. In the applicant¡¯s myeloma and breast cancer trials, treatment with pamidronate resulted in both a decrease in the proportion of patients with at least one SRE and an increase in time to first SRE. Recently, a second bisphosphonate, zoledronate, was approved on the basis of similar end points. Composite end points can also be constructed from symptoms. Clinical benefit response¡ªa composite end point of pain, performance status, and weight gain¡ªwas supportive of regular approval of gemcitabine for treatment of pancreatic cancer, although a small, statistically significant survival improvement was the primary approval basis.

Doest the sentence mean the ¡°The end points¡± are be related to one another, or they are related to clinical importance? I saw a Chinese version of the sentence (¡°The end-point components should be related and generally of similar clinical importance¡±) in a book, which if translated again into English literally means that the composition of the end-points should be related to clinical importance? Is the Chinese version makes sense?